Form 4: Nuvalent CSO Exercises Options, Sells Shares

Nuvalent's Chief Scientific Officer, Henry E. Pelish, exercised stock options and subsequently sold a portion of his Class A Common Stock shares under a pre-arranged 10b5-1 trading plan.

Summary

• Henry E. Pelish, Nuvalent, Inc.'s Chief Scientific Officer, engaged in transactions involving the company's Class A Common Stock on October 15, 2025.
• Pelish exercised stock options to acquire a total of 14,205 shares of Class A Common Stock.
• The options were exercised at prices of $18.93 for 3,668 shares, $27.85 for 7,495 shares, and $72.35 for 3,042 shares.
• Following the option exercises, Pelish sold 14,205 shares of Class A Common Stock at a weighted average price of $90.04 per share, with individual sales ranging from $89.84 to $90.23.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 1, 2024.
• After these transactions, Pelish directly beneficially owns 65,963 shares of Class A Common Stock.
• Pelish also retains beneficial ownership of derivative securities, including 10,569 stock options with an exercise price of $18.93, 13,156 stock options with an exercise price of $27.85, and 24,058 stock options with an exercise price of $72.35.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction (exercise of options and subsequent sale) conducted under a pre-arranged 10b5-1 trading plan, which is common for executive compensation and personal financial management.

Positives

• The Chief Scientific Officer realized significant personal gains by exercising options at substantially lower prices ($18.93, $27.85, $72.35) and selling shares at a weighted average price of $90.04, indicating a strong market value for Nuvalent's stock at the time of sale.

Negatives

• The sale of 14,205 shares by a key executive, even under a pre-arranged plan, could be interpreted by some investors as a move to diversify away from the company's stock, potentially signaling a perceived ceiling in its near-term valuation.

Risks

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a negative signal, potentially leading to downward pressure on the stock price if investors interpret it as a lack of confidence from management.

Future Outlook

This Form 4 filing does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports a routine insider transaction, which is common across all industries as executives manage their personal equity holdings. It does not provide specific insights into broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• The transactions involve the Chief Scientific Officer of Nuvalent, Inc. exercising stock options granted by the company and subsequently selling shares of the company's stock.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the pre-arranged nature under a 10b5-1 plan mitigates negative implications compared to an unplanned sale.
• Employees: No direct impact mentioned, but executive compensation practices are generally observed.

Next Steps

• Continued vesting of the remaining stock options held by the Chief Scientific Officer, subject to continued service to Nuvalent, Inc.

Key Dates

Recommendation

The filing details a routine insider transaction where the Chief Scientific Officer exercised vested stock options and sold a portion of the resulting shares under a pre-arranged 10b5-1 trading plan. While insider sales can sometimes be a negative signal, the pre-planned nature of these transactions suggests personal financial management rather than a reaction to new, undisclosed negative information about the company. This single transaction, therefore, is unlikely to fundamentally alter the investment thesis for Nuvalent, Inc., warranting a 'hold' recommendation for seasoned investors.

Keywords

NUVL, Nuvalent, Insider Trading, Form 4, Stock Options, Executive Compensation, Rule 10b5-1 Plan, Chief Scientific Officer